Sage Journals: Discover world-class research

Abstract

Few HIV physicians are trained to provide buprenorphine treatment. We conducted a cross-sectional survey to assess the impact of an eight-hour course on the treatment of opioid dependence on HIV physicians’ preparedness to prescribe buprenorphine. One hundred thirteen of 257 trained physicians (44%) provided HIV care. Post-course, the majority of both HIV physicians and non-HIV physicians (66% vs. 67%, P =.8) planned to pursue a registration to prescribe buprenorphine. The most common reason for not planning to do so was lack of experience (9% vs. 15%, P =.19). Fifty-two of the 113 (46%) HIV physicians had concerns about prescribing buprenorphine. Thirty of the 52 (58%) indicated that interactions between buprenorphine and HAART was their primary concern. Following training, most physicians feel prepared and plan to obtain a registration to prescribe buprenorphine. HIV physicians’ concerns regarding interactions between buprenorphine and HAART need to be addressed in future training efforts.

Keywords

Education buprenorphine substance-related disorders HIV physicians

Get full access to this article

View all access options for this article.

References

Fiellin

D. A.

, Butler

, D'Onofrio

, Brown

R. L.

and O'Connor

P. G.

2002. The physician's role in caring for patients with substance use disorders: Implications for medical education and training. Substance Abuse, 23(3): 207–222.

Turner

B. J.

, Fleishman

J. A.

, Wenger

, London

A. S.

, Burnam

M. A.

Shapiro

M. F.

2001. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. Journal of General Internal Medicine, 16(9): 625–633.

Wong

M. D.

, Cunningham

W. E.

, Shapiro

M. F.

, Andersen

R. M.

, Cleary

P. D.

Duan

2004. Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients. Journal of General Internal Medicine, 19(4): 366–374.

Bassetti

, Battegay

, Furrer

, Rickenbach

, Flepp

Kaiser

1999. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 21(2): 114–119.

Ding

, Landon

B. E.

, Wilson

I. B.

, Wong

M. D.

, Shapiro

M. F.

and Cleary

P. D.

2005. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Archives of Internal Medicine, 165: 618–623.

Jaffe

J. H.

and O'Keeffe

2003. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug and Alcohol Dependence, 70(2, Supplement 1): S3–S11.

2000. Drug Addiction Treatment Act of 2000

Moatti

J. P.

, Souville

, Escaffre

and Obadia

1998. French general practitioners’ attitudes toward maintenance drug abuse treatment with buprenorphine. Addiction, 93(10): 1567–1575.

Fiellin

D. A.

, O'Connor

P. G.

, Chawarski

M. C.

, Pakes

J. P.

, Pantalon

M. V.

and Schottenfeld

R. S.

2001. Methadone maintenance in primary care: A randomized controlled trial. JAMA, 286: 1724–1731.

10.

Godden

, Byrne

, Wanigaratne

and Feinmann

1997. Care and shared care of opiate misusers by general practitioners in inner London. J Subst Misuse Nursing, Health & Social Care, 2(4): 217–221.

11.

Wong

J. G.

, Kraus

M. L.

, Feinberg

M. A.

and Fiellin

D. A.

2003. Providing opioid agonist maintenance therapy in a generalist's office: The physician's perspective. Substance Abuse, 24(1): 1–3.

12.

McCance-Katz

E. F.

, Pade

, Exhem-Williams

, Hellew

, Moody

and Rainey

P. M.

2004. Concomitant administration of buprenorphine and efavirenz is not associated with opiate abstinence symptoms in opioid-dependent individuals. Paper presented at the College of Problems on Drug Dependence Proceedings of the 66th Annual Scientific Meeting, San Juan. 2004, Puerto Rico.

13.

McCance-Katz

E. F.

, Rainey

P. M.

, Friedland

, Kosten

T. R.

and Jatlow

2001. Effect of opioid dependence pharmacotherapies on zidovudine disposition. American Journal on Addictions, 10(4): 296–307.

14.

Carrieri

M. P.

, Vlahov

, Dellamonica

, Gallais

, Lepeu

Spire

2000. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug & Alcohol Dependence, 60(1): 51–54.

15.

Woo

, Sullivan

L. E.

, Chang

and Kubin

2004. Pain management/addiction management medications and HIV antiretrovirals: A guide to interactions for clinicians, New York: NY/NJ AIDS Education and Training Center/Columbia University.

16.

Department of Health and Human Services, H. R. a. S. A., HIV/AIDS Bureau. 2004. An evaluation of innovative methods for integrating buprenorphine opioid abuse treatment in HIV primary care settings: 1) Demonstration models and 2) Evaluation and support center Retrieved May 1, 2005, from http://hab.hrsa.gov/special/%5CSPNS05RPT%5Cbup.htm

Training HIV Physicians to Prescribe Buprenorphine for Opioid Dependence

Abstract

Keywords

Get full access to this article

References